Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$2.17 ▲ +0.00
(0.00%)
MKT CAP: $260.0M • VOL: 804.3K
52W L $1 52W H $3
ROARABLE / RQD
D- • 40/100
PIOTROSKI
3 / 9
FATE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $6.6M | $13.6M | $63.5M |
| YoY Revenue Growth % | -51.2% | -78.5% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$147.7M | -$210.3M | -$190.5M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$136.3M | -$186.3M | -$160.9M |
| EBITDA (Normalized) | -$142.9M | -$209.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$106.1M | -$122.9M | -$132.3M |
| Capital Expenditures (CapEx) | $6.0M | $730.0K | — |
| Free Cash Flow (FCF) | -$112.0M | -$123.6M | -$132.3M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $46.6M | $36.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $207.2M | $318.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR FATE.